Sign In
Buy CMPS
$12.69
-0.640 (-4.80%)
At Close: Jun 03, 2026
COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of “Moderate Buy” from Analysts
02:24am, Wednesday, 18'th Feb 2026
COMPASS Pathways PLC Sponsored ADR (NASDAQ: CMPS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are currently covering the company, M
COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials Transcript
05:14pm, Tuesday, 17'th Feb 2026
COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials Transcript
Compass Pathways Launches Proposed $150.0 Million Public Offering
04:06pm, Tuesday, 17'th Feb 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod
Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot
02:43pm, Tuesday, 17'th Feb 2026
Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot
Why Did Compass Pathways Stock Rocket Higher Today?
11:35am, Tuesday, 17'th Feb 2026
Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome.
Compass Pathways' depression treatment meets main goal in late‑stage study
06:42am, Tuesday, 17'th Feb 2026
Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod
COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Short Interest Update
02:10am, Tuesday, 17'th Feb 2026
COMPASS Pathways PLC Sponsored ADR (NASDAQ: CMPS - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest tota
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
08:00am, Monday, 16'th Feb 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tha
COMPASS Pathways Plc ADR (CMPS) Price Forecast: Bullish Reversal Gains Structure
05:01pm, Monday, 09'th Feb 2026
COMPASS Pathways shares show an early bullish trend, with a falling-wedge breakout holding key long-term support and setting up higher targets ahead of late-February earnings.
Compass Pathways: Exciting Prospects For This Psychedelic Pioneer With Significant Risks
01:25pm, Thursday, 08'th Jan 2026
Compass Pathways plc experienced an >80% rally since my last 'Hold' rating. CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Recent app
COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression Transcript
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
06:30am, Wednesday, 07'th Jan 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced toda
COMPASS Pathways (NASDAQ:CMPS) and GoodRx (NASDAQ:GDRX) Financial Analysis
01:58am, Sunday, 21'st Dec 2025
COMPASS Pathways (NASDAQ: CMPS - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies
